Steward Partners Investment Advisory LLC Has $172,000 Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Steward Partners Investment Advisory LLC boosted its position in shares of West Pharmaceutical Services, Inc. (NYSE:WSTGet Rating) by 18.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 418 shares of the medical instruments supplier’s stock after purchasing an additional 64 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in West Pharmaceutical Services were worth $172,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Modera Wealth Management LLC acquired a new position in West Pharmaceutical Services during the fourth quarter valued at approximately $285,000. ARK Investment Management LLC bought a new position in West Pharmaceutical Services in the first quarter valued at approximately $179,000. Kestra Advisory Services LLC lifted its stake in West Pharmaceutical Services by 7.5% in the first quarter. Kestra Advisory Services LLC now owns 3,124 shares of the medical instruments supplier’s stock valued at $1,283,000 after buying an additional 219 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in West Pharmaceutical Services by 10.6% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 167,783 shares of the medical instruments supplier’s stock valued at $78,693,000 after buying an additional 16,138 shares in the last quarter. Finally, Mirabella Financial Services LLP lifted its stake in West Pharmaceutical Services by 70.3% in the fourth quarter. Mirabella Financial Services LLP now owns 21,864 shares of the medical instruments supplier’s stock valued at $10,254,000 after buying an additional 9,024 shares in the last quarter. Institutional investors and hedge funds own 93.25% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $343.56 on Monday. The company’s fifty day simple moving average is $305.13 and its 200-day simple moving average is $348.71. The company has a quick ratio of 2.18, a current ratio of 2.89 and a debt-to-equity ratio of 0.09. The firm has a market cap of $25.45 billion, a PE ratio of 38.17, a P/E/G ratio of 3.64 and a beta of 1.13. West Pharmaceutical Services, Inc. has a 12 month low of $275.89 and a 12 month high of $475.35.

West Pharmaceutical Services (NYSE:WSTGet Rating) last announced its quarterly earnings data on Thursday, July 28th. The medical instruments supplier reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.28. The business had revenue of $771.30 million for the quarter, compared to analyst estimates of $754.25 million. West Pharmaceutical Services had a net margin of 23.76% and a return on equity of 30.33%. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.46 earnings per share. Equities research analysts expect that West Pharmaceutical Services, Inc. will post 9.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Thursday, April 28th.

West Pharmaceutical Services Profile

(Get Rating)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Stories

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Want More Great Investing Ideas?

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.